Biohaven Ltd. (NYSE:BHVN) Shares Purchased by US Bancorp DE

US Bancorp DE grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 57.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,173 shares of the company’s stock after buying an additional 790 shares during the quarter. US Bancorp DE’s holdings in Biohaven were worth $109,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Biohaven in the 1st quarter valued at $644,000. Swiss National Bank grew its stake in shares of Biohaven by 6.3% in the first quarter. Swiss National Bank now owns 142,500 shares of the company’s stock valued at $7,793,000 after buying an additional 8,400 shares in the last quarter. Sei Investments Co. grew its stake in shares of Biohaven by 25.4% in the first quarter. Sei Investments Co. now owns 18,440 shares of the company’s stock valued at $1,008,000 after buying an additional 3,730 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Biohaven by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 12,291 shares of the company’s stock valued at $672,000 after buying an additional 967 shares during the period. Finally, Vanguard Group Inc. lifted its position in Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after acquiring an additional 4,650,702 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

BHVN has been the topic of a number of recent analyst reports. UBS Group cut their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upped their price target on shares of Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd. Sanford C. Bernstein raised their price objective on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a report on Tuesday, September 24th. Bank of America boosted their target price on shares of Biohaven from $52.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Finally, TD Cowen increased their price target on shares of Biohaven from $55.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $63.42.

Biohaven Trading Down 8.8 %

NYSE:BHVN opened at $44.39 on Friday. Biohaven Ltd. has a 1 year low of $26.80 and a 1 year high of $62.21. The stock has a 50-day moving average price of $48.16 and a two-hundred day moving average price of $40.92. The stock has a market cap of $4.49 billion, a price-to-earnings ratio of -4.75 and a beta of 1.31.

Biohaven (NYSE:BHVN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). Sell-side analysts forecast that Biohaven Ltd. will post -8.81 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gregory Bailey purchased 5,000 shares of Biohaven stock in a transaction dated Tuesday, September 24th. The shares were bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the acquisition, the director now owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. This trade represents a 0.31 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John W. Childs purchased 21,052 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average cost of $47.50 per share, with a total value of $999,970.00. Following the purchase, the director now directly owns 21,052 shares of the company’s stock, valued at approximately $999,970. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is owned by company insiders.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.